Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: Results from a randomized control study

Abstract

Responsiveness to infliximab treatment is highly heterogeneous among individuals with AS, and this parameter overcomes the circulating infliximab concentration to explain treatment success or failure.